SCHEMBL2179986

SCHEMBL2179986

CC(C)[C@@H](C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)c4ccccc4C(F)(F)F)cc3)cc2C1=O

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 1/20 0.46
LMNA P02545 2/20 0.44
TP53 P04637 1/20 0.44
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
SDCBP O00560 3/20 0.43
SDC2 P34741 3/20 0.43
KCNK3 O14649 2/20 0.41
KCNK9 Q9NPC2 2/20 0.41
THRB P10828 2/20 0.41
PTGES O14684 1/20 0.40
PTGS1 P23219 1/20 0.39
RECQL P46063 1/20 0.39
EGFR P00533 1/20 0.39
F2R P25116 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2179993 1.00 PTPRC (0.46) PTPRCLMNATP53PDE3BPDE3A
SCHEMBL2177533 0.92 LMNA (0.40) PTPRCLMNATP53PDE3BPDE3A
SCHEMBL2177537 0.92 LMNA (0.40) PTPRCLMNATP53PDE3BPDE3A
SCHEMBL2179906 0.91 LMNA (0.47) PTPRCLMNATP53PDE3BPDE3A
SCHEMBL2179776 0.90 LMNA (0.43) LMNATP53SDCBPSDC2THRB
SCHEMBL2179769 0.90 LMNA (0.43) LMNATP53SDCBPSDC2THRB
SCHEMBL2177338 0.87 ITGA4 (0.43) LMNATP53SDCBPSDC2THRB
SCHEMBL2177345 0.87 ITGA4 (0.43) LMNATP53SDCBPSDC2THRB
SCHEMBL2177068 0.86 SMO (0.53) LMNATP53SDCBPSDC2
SCHEMBL2181361 0.86 SMO (0.53) LMNATP53SDCBPSDC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT PTPRC 1976/4885LMNA 2193/4885TP53 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.